2025 has been a year of tranisition and execution. We have moved from technology validation to a fully integrated and controlled system - enabling us to produce the same implant with the same functionality, every time. This positions us to further optimise manufacturing processes and meet regulatory expectations as we progress toward clinical studies and commercialisation. This has been a decisive transition for Lifecare.

While 2024 demonstrated our sensor technology in an implantable format, 2025 was about converting that breakthrough into a robust, repeatable and scalable system. During the year, we moved from validating feasibility to demonstrating controlled, system-level execution of a fully integrated implantable Continuous Glucose Monitoring platform. This milestone significantly reduces the platform’s technical risk profile. Lifecare now moves forward with clear priorities: progressing regulatory approvals for first-in-human trials followed by the regulatory CE trial.

The Annual Report is published in both the European Single Electronic Format (ESEF) and as a PDF. 

Additionally, Lifecare has published its 2025 Remuneration Report in accordance with the Norwegian Public Limited Liability Companies Act, section 6-16b (2). 

The reports are available on Lifecare’s website: https://lifecare.no/investor/reports-presentations/.